The KLF4 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal HeLa cell population with targeted disruption of the KLF4 gene, creating a loss-of-function model for Kr??ppel-like factor 4 studies. This polyclonal format provides a heterogeneous knockout population free of clonal artifacts, suitable for bulk assays where gene disruption is validated at the population level, making it a versatile tool for cervical cancer research.
Derived from cervical adenocarcinoma, HeLa cells are a human epithelial line harboring HPV18 sequences that inactivate p53 and Rb, offering a distinctive context for tumor suppressor analysis. They maintain epithelial characteristics, supporting studies of differentiation, barrier integrity, and signaling. Their genetic stability and widespread use ensure reproducibility in knockout experiments and compatibility with diverse assays.
KLF4 is a zinc-finger transcription factor that binds GC-rich DNA elements to regulate cell cycle, apoptosis, and epithelial differentiation. It is activated by upstream signals including TGF-??, Wnt ligands, and p53, and functions in the TGF-??/SMAD pathway where TGF-?? receptor activates SMAD2/3-SMAD4 to induce KLF4. KLF4 transcriptionally activates p21/CDKN1A and represses Cyclin D1, driving cell cycle arrest. It interacts with Oct4, Sox2, the coactivator p300/CBP, the corepressor HDAC1, and ??-catenin, integrating cross-talk between pluripotency, Wnt, and TGF-?? pathways.
In cervical cancer, KLF4 generally suppresses growth by inducing p21, though it may exhibit oncogenic roles in other contexts. The HeLa background, with disrupted p53 and Rb, permits dissection of KLF4??s p53-independent tumor suppressor mechanisms and its interaction with HPV oncoproteins. This knockout model is valuable for examining KLF4??s contributions to epithelial barrier maintenance, stemness, and chemoresistance??areas where functional understanding remains incomplete.
This product supports functional genomics of KLF4 in cervical cancer, epithelial differentiation studies, drug resistance screens, and pluripotency network analysis. Typical assays include Western blotting, RT-qPCR, and immunofluorescence for knockout validation; proliferation, apoptosis, and migration assays for functional readouts; and RNA-seq or ChIP-qPCR for global transcriptional and chromatin-binding studies. This polyclonal knockout population provides a robust platform for advanced biomedical research. For further details, contact Ascent Research.
